Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF.

Vilnius, Lithuanian National Tuberculosis Control Programme, 2011. 3 Bakonyte D, Baranauskaite A, Cicenaite J, et al. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob Agents Chemother 2003; 47: 2009–2011. 4 Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 2009; 150: 766–775. 5 Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000– 2004. Eur Respir J 2010; 36: 584–593. 6 Podewils LJ, Holtz T, Riekstina V, et al. Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients. Epidemiol Infect 2011; 139: 113–120. 7 Drobniewski F, Balabanova Y, Nikolayevsky V, et al. Drugresistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 2005; 293: 2726–2731. 8 Mokrousov I, Otten T, Zozio T, et al. At Baltic crossroads: a molecular snapshot of Mycobacterium tuberculosis population diversity in Kaliningrad, Russia. FEMS Immunol Med Microbiol 2009; 55: 13–22. 9 Kruuner A, Hoffner SE, Sillastu H, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001; 39: 3339–3345. 10 Tracevska T, Jansone I, Baumanis V, et al. Prevalence of Beijing genotype in Latvian multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2003; 7: 1097–1103.